ADRB2 and neoplasm: Moreover, adrenergic signaling modulates T cell entry and exit via ADRB2; inhibiting ADRB2 amplifies the cytotoxic effects and migratory abilities of CD8+ T cells, therefore inhibiting tumor proliferation (99).